This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
Alopecia Areata, Vitiligo
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
-
Dren Investigational Site, Northridge, California, United States, 91344
Dren Investigational Site, Miami, Florida, United States, 33155
Dren Investigational Site, Evans, Georgia, United States, 30809
Dren Investigational Site, Meridian, Idaho, United States, 83642
Dren Investigational Site, Indianapolis, Indiana, United States, 46250
Dren Investigational Site, West Lafayette, Indiana, United States, 47906
Dren Investigational Site, Worcester, Massachusetts, United States, 01605
Dren Investigational Site, Troy, Michigan, United States, 48084
Dren Investigational Site, Philadelphia, Pennsylvania, United States, 19103
Dren Investigational Site, Pittsburgh, Pennsylvania, United States, 15213
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Dren Bio,
Michael Rothenberg, MD, PhD, STUDY_DIRECTOR, Dren Bio
2026-09